Home > Healthcare > Medical Devices > Implantable Devices > Sleep Apnea Implants Market
Based on product, the market is segregated as hypoglossal neurostimulation devices, palatal implants, bone screw system, and phrenic nerve stimulators. The hypoglossal neurostimulation devices accounted for majority market share in 2021 and is expected to register over 16.8% CAGR during the estimation timeframe. This majority market share is pertaining to rapid adoption of hypoglossal neurostimulation devices and higher efficacy in managing obstructive sleep apnea.
Hypoglossal nerve stimulation arose as an effective mechanism for muscle stimulation. The hypoglossal nerve regulates the movement of tongue and airway muscles. By stimulating this nerve, hypoglossal neurostimulation assists in maintaining an open airway during sleep. Over the last decade, novel technologies concentrating on the stimulation of hypoglossal nerve have emerged as a therapeutic alternative for individuals suffering with moderate-to-severe OSA patients that are non-compliant with conventional CPAP therapy. Further, the ongoing clinical studies & R&D efforts to assess and promote efficacy is set to proliferate the sleep apnea implants market share.
The obstructive sleep apnea segment was valued at around USD 286 million in 2021 and is anticipated to grow at 16.6% CAGR from 2022-2030. This dominant market growth is majorly attributed to the high prevalence of obstructive sleep apnea. According to an article published by the National Centers for Biotechnology Information, in 2019, obstructive sleep apnea is a condition characterized by recurrent upper airway obstruction during sleep.
This disorder affects approximately 6% to 7% population and is concerned with surged recurrence of cardiovascular disease, stroke, daytime sleepiness, and reduced quality of life. These symptoms are majorly observed in patients suffering with moderate-to-severe OSA, referred to as apneahypopnea index (AHI) greater than 15 events per hour. Thus, the significant prevalence of OSA is expected to expedite the industry expansion.
The ambulatory surgical centers segment accounted for significant market share of more than 41% in 2021 and is expected to register a significant CAGR during the analysis period. This dominant market share is owing to the surged adoption of these implants and implantation procedures in these healthcare settings.
Ambulatory surgical centers provide novel surgical technology, advanced implants, and these treatments are being offered by certified surgeons & healthcare professionals that secures the overall market expansion and drives the preference for these facilities. Moreover, availability and surging demand for surgical procedures at these healthcare settings for better patient management and care further accelerates the sleep apnea implants market growth in the coming years.
U.S. sleep apnea implants market is projected to reach more than USD 967 million by 2030. This dominant market share is owing to several factors such as the rising prevalence & incidence of OSA, high OSA associated disease burden, product launches, and presence of major players across the country. According to the Lancet Respiratory journal statistics in 2019, approximately 23.6 million people were suffering from OSA in the U.S. The considerable OSA population base has led to incremental surge in the OSA associated economic burden.
Further, the low awareness regarding OSA and underdiagnosed cases represent significant market development opportunity for the key players. According to Nyxoah’s 2021 annual report, OSA remains notably underdiagnosed with the diagnosis rate in the U.S. averaged at 18%. Also, the presence of major players in the country launching novel products is expected to benefit the market in the U.S.